Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Ampio Pharmaceuticals Dropped as Much as 18.8% Today

By Maxx Chatsko - Feb 16, 2018 at 3:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What goes up must come down.

What happened

Shares of development-stage pharma Ampio Pharmaceuticals (AMPE -9.75%) fell nearly 19% today without any news. However, considering the stock rose over 20% earlier in the week -- once again, without any news -- today's move is likely just a simple correction. Even with the precipitous drop factored in, the stock is up 210% in the last year, although the company's market cap is just $190 million.

As of 2:55 p.m. EST, the stock had settled to a 17.9% loss.

So what

Investors have been cheering on Ampio Pharmaceuticals for seemingly rosy data on its lead drug candidate Ampion, which is a potential treatment for severe osteoporosis of the knee. The company released and explained phase 3 results for the drug candidate at the end of 2017. But marketing approval may not be coming.

A finger pointing at a candle chart showing losses.

Image source: Getty Images.

Why not? As explained by prominent biopharma analyst Adam Feuerstein over at STAT, the phase 3 trial wasn't accompanied by the most robust design. Turns out, Ampion has performed no better than saline solution for treating osteoporosis.

Now what

Ampio Pharmaceuticals doesn't have a great reputation, has never generated revenue, and has worked hard to spin mediocre trial data as something more positive. I think the market had the company more fairly valued in the second half of 2017 when it was a penny stock with little going for it. In other words, today's big drop probably won't be the last.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ampio Pharmaceuticals, Inc. Stock Quote
Ampio Pharmaceuticals, Inc.
AMPE
$0.16 (-9.75%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.